https://www.selleckchem.com/pr....oducts/ziritaxestat.
2, 11.8, 15.9, and 21.0%, respectively. The mortality rate at day 30 was significantly better (p = 0.04) in group 1, but no further differences in survival were observed (hazard ratio 1.071; 95% confidence interval 0.864-1.328; log rank 0.179). A subgroup analysis of geriatric patients ≥ 65years assessed no differences according the primary and secondary endpoints. Within the limits of single-center analysis, the patients receiving treatment for HF within 12h were younger and healthier and had the benefits of shorter hospitalizatio
Like
Comment
Share
